Cancer immunotherapy is built on a simple but powerful idea: the immune system can recognize and destroy cancer cells if it is properly activated. In many patients, however, this response is too weak or too slow to be effective. Recently, a type of immune cell called invariant natural killer T (iNKT) cells has attracted attention because of their ability to act as coordinators of immune responses, rapidly activating and rallying other immune cells to fight cancer.
This article was originally published on MedicalXpress.com
